Moderna cancer vaccine trial data shows positive results
Story essentials
Moderna, Merck
Global
October 22, 2026
This page is produced by collecting and structuring multiple public reports. Sections based only on reporting or testimony affect the displayed assessment, and the page is updated when new information is identified.
About this article
COMPAMIR Editorial Team
The COMPAMIR editorial team brings together public reporting and links to the original coverage. We update the page as new information emerges.
Read our editorial policy- Earlier version 110/22/2026, 11:20:44 PM
Moderna's personalized cancer vaccine, combined with Merck's Keytruda, reduced recurrence or death risk in melanoma patients by 42%. The vaccine also reduced the risk of cancer spreading to distant parts of the body by 38%. Moderna shares dropped 25% following a leak of partial data, despite positive full results.
Read next
Prioritized by shared people, places, and events.
Meta reports negative free cash flow and increases capital expenditure forecast
Meta reported negative free cash flow of $2.12 billion for the third quarter. Full-year capital expenditure forecast raised to $135 billion - $145 billion. Company to create new nonvoting Class C stock to maintain founder-led structure.